News | Implantable Cardioverter Defibrillator (ICD) | January 17, 2017

Study Finds High Survival Rate for Elderly Patients with Implantable Defibrillator

Patients received device after sudden cardiac arrest or near-fatal arrhythmia

ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study

January 17, 2017 — Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac arrest or a near-fatal arrhythmia, almost 80 percent survived two years, according to a new study in the Journal of the American College of Cardiology. This is a higher rate than found in past trials performed to demonstrate the efficacy of the devices in this situation.

Patients who survived sudden cardiac arrest or had a near-fatal fast heart rhythm, called an arrhythmia, are sometimes treated with an ICD to prevent future cardiac arrest. An ICD is placed under the skin and connected to the heart with wires, which detects when the heartbeat is irregular and can return the heart rhythm to normal with an electrical shock—also known as defibrillation.

“In this population, there is a very high risk for these cardiac events to happen again,” said the study’s lead author, Frederick Masoudi, M.D., MSPH, professor of medicine at the University of Colorado Anschutz Medical Campus and the chief science officer of the American College of Cardiology’s National Cardiovascular Data Registry. “I was surprised to see the survival rates in our study were as high as they were.”

Masoudi said the findings suggest that physicians are doing a good job of selecting elderly patients for the implantable defibrillators.

Past randomized clinical trials of ICDs were relatively small, were conducted several decades ago and did not include many older patients. ICD technology and treatment for underlying heart disease have since improved, Masoudi said. In an analysis of these clinical trials, the risk of death for patients at least 75 years of age was approximately 35 percent among those receiving an ICD, compared with 22 percent in the current study, in which 75 percent of the population was at least 75 years old.

“It’s important to study older patients, because they often have other co-existing medical conditions, which may have an impact on their outcomes,” Masoudi said.

Using data from NCDR’s ICD Registry, the study included 12,420 Medicare beneficiaries undergoing an ICD implantation after surviving sudden cardiac arrest or a near-fatal ventricular arrhythmia, between 2006 and 2009 in almost 1,000 U.S. hospitals.

The researchers found 65.4 percent of patients were hospitalized during the two years after receiving an ICD, ranging from 60.5 percent in those less than age 70 to 71.5 percent in those 80 and older. In addition, 13.1 percent among those less than 70 years old and 21.9 percent of those 80 and older were admitted to a skilled nursing facility. The risk of admission to a skilled nursing facility was greatest in the first 30 days after the procedure. The risks of hospitalization and admission to skilled nursing facility were all greater with increasing patient age.

The researchers noted that the high hospitalization and skilled nursing facility admission rates, particularly among the oldest patients, indicate there are substantial care needs after an ICD is implanted.

“This gives us a good picture of the healthcare needs of this population after their procedure,” Masoudi said.

Limitations include that the study was not designed to evaluate the effectiveness of ICDs and did not compare the patients receiving the devices with a control group who did not receive them.

In an editorial accompanying the study, Sumeet S. Chugh, M.D., associate director of the Cedars-Sinai Heart Institute, wrote that the findings from the new study would suggest that although patients over age 75 implanted with ICDs after a sudden cardiac arrest or near-fatal ventricular arrhythmia “may have reasonable overall survival, they also have significantly high rates of admission to hospitals and skilled nursing facilities, with no clear evidence of mortality benefit from the device.”

He said that until more research is done about the devices in elderly patients, doctors should consider non-heart-related co-occurring medical conditions and frailty along with age in their decision-making process about ICDs. They should provide the patient with a clear understanding of the rationale and limitations of the ICD, encourage advance directives and bring up the possibility of deactivating the ICD if the patient is nearing end of life.

For more information: www.jacc.org

References

Betz, J.K., Katz, D.F., Peterson, P.N., Borne, R.T., et al. "Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention," Journal of the American College of Cardiology. Published online Jan. 16, 2017.DOI: https://doi.org/10.1016/j.jacc.2016.10.062

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init